AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04978168 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Participants randomized to TAU will receive the services that will be offered at the time the Core Implementation intervention is completed.
Study NCT04310423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched to endotoxin
Study NCT04310423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Bolus dose of 0.8 ng/kg
Study NCT05837494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular Ozone and corticosteroids
Description: patients will undergo one session a week for a total of four sessions of intra-articular knee injection with combination of 5ml (25 μg/ml) ozone injection + 2 ml lignocaine 2% + 2 ml Betamethasone sodium phosphate 4 mg.~Under aseptic precautions. A22-gauge needle was positioned inferior-laterally into the infera-patellar pouch, injection of 2 ml of 4 mg Betamethasone sodium phosphate, and 2 ml injection lignocaine 2% was injected slowly (over 1-2 minutes). The needle was left in space for the 5 ml (25 μg/ml) ozone injection. Patients were advised to avoid strenuous activity for 2-3 days following the intra-articular injection.
Study NCT05837494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-articular PRGF Method
Description: Patients will undergoes two doses with 2 weeks interval by injection of already synthetic plasma rich in growth factors \[PRGF\] vial intra-articularly.~This vial is formed of lyophilized cake of platelet growth factors in a tightly sealed container stored at 2-8◦C which synthesized under complete aseptic technique by activation of platelets to release its growth factors and cytokines which help in knee cartilage regeneration and act as potent anti-inflammatory to reduce the pain.~Prior to usage, reconstitution of the product was done using 1 ml saline and 1 ml lignocaine 2% followed by gentle vial rubbing for 3 min then, the mixture was kept at ambient temperature for 5 min to ensure complete protein re-hydration.
Study NCT05130242 — intervention group
Intervention type: PROCEDURE
Intervention: Cement-augmented Pedicle Screws (CPS)
Description: Patients who received surgical treatment with CPS for osteoporotic fractures in the thoracic or lumbar spine
Study NCT05130242 — intervention group
Intervention type: PROCEDURE
Intervention: Hybrid Construct (HC)
Description: Patients who received surgical treatment with HC consisting of pedicle screws and additional hooks for osteoporotic fractures in the thoracic or lumbar spine
Study NCT04690868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-213-A
Description: 1 tablet administered before the breakfast during 5 days
Study NCT04690868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2131
Description: 1 tablet administered before the breakfast during 5 days
Study NCT05359497 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Liver Multiscan sequences baseline
Description: Additional Liver Multiscan sequences at baseline besides standard care MRI liver /MRCP prior to ERCP.
Study NCT05359497 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRCP+ analysis baseline
Description: Post processing tool (Software) for quantifying MRCP images after MRCP is performed. Patient involvement is not necessary during this procedure.
Study NCT05359497 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Liver Multiscan analysis baseline
Description: Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
Study NCT05359497 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI liver with MRCP
Description: An extra MRI liver with contrast and MRCP is performed 8 weeks after the ERCP following standard care protocol
Study NCT05359497 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Liver Multiscan sequences follow-up
Description: Additional Liver Multiscan sequences are performed at 8 weeks after ERCP.
Study NCT05359497 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRCP+ analysis follow up
Description: Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
Study NCT05359497 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Liver Multiscan analysis follow up
Description: Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences from the follow up scan are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
Study NCT05236478 — intervention group
Intervention type: OTHER
Intervention: CoviMouv' program
Description: * An initiation to physical rehabilitation at the hospital center the first week, 3 sessions of 1 hour.~* A tele-rehabilitation program led by an Adapted Physical Activity (APA) teacher for 3 weeks with 3 sessions of 1 hour per week.~All the sessions are led by a professional of adapted physical activity and will be personalized and adapted to the functional tests carried out during the initial evaluation.~* Therapeutic education video-workshops weekly: about (i) the pathophysiology of fatigue in COVID-19, (ii) returning to work, (iii) lifestyle: sleep, physical activity and diet.~* The medical follow-up will be carried out remotely with 1 weekly teleconsultation with a physiologist.~* Psychological and / or dietetic follow-up, if necessary, during the program: 1 weekly teleconsultation At the end of the program, each participant is invited to contact the sport-health platform in order to continue the Adapted Physical Activity (APA) practice near home for 2 months.
Study NCT05236478 — intervention group
Intervention type: OTHER
Intervention: Control
Description: The CoviMouv' program is not presented to theses patients They have support for the resumption of an adapted physical activity in autonomy, according to the results of the aerobic and anaerobic tests carried out during the initial evaluation (delivery of a training booklet).
Study NCT05077657 — intervention group
Intervention type: DEVICE
Intervention: Early Bird® Bleed Monitoring System
Description: The Early Bird Bleed Monitoring System is used in endovascular procedures to monitor and detect internal bleeding complications in real-time.
Study NCT05077657 — intervention group
Intervention type: DEVICE
Intervention: Impella®
Description: Impella is an FDA-approved percutaneous heart pump indicated for patients with severe coronary artery disease requiring high-risk PCI.
Study NCT06244446 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention. It is an observational study
Study NCT05401760 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A :combined phacoaspiration and angle surgery
Description: * Partial thickness scleral flap to access the canal of schlemm.~* 2 side ports will be fashioned.~* Trypan blue will be injected to aid visualization of the anterior capsule \& continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~* The nucleus and cortex will be aspirated.~* Posterior capsulrehxis and limited anterior vitrectomy will be done.~* Corneal incisions will be sutured with 10-0 Nylon suture.~* Using metal trabeculotomes to open thetrabecular meshwork after accessing the canal of schlemm.~* Suturing of scleral flap with 10-0 Nylon suture.
Study NCT05401760 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B : phacoaspiration only
Description: * 2 side ports will be fashioned.~* Trypan blue will be injected to aid visualization of the anterior capsule \& continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~* The nucleus and cortex will be aspirated.~* Posterior capsulrehxis and limited anterior vitrectomy will be done.~* Corneal incisions will be sutured with 10-0 Nylon suture.
Study NCT05681182 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: CardiaMend with the Addition of Amiodarone
Description: The CardiaMend patch will be saturated with Amiodarone prior to being sutured into place.
Study NCT06431152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSC sEV
Description: Small extracellular vesicles derived from allogenic mesenchymal stromal cells, single dose
Study NCT05311891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RT PCR
Description: Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
Study NCT04513223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: There are six pre-defined dose regimens . Subjects will be enrolled with an initial dose
Study NCT05957380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2803
Description: All participants are administered one tablet per day for 48 weeks
Study NCT05957380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2803-R
Description: All participants are administered one tablet per day for 48 weeks
Study NCT05957380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of DA-2803
Description: All participants are administered one tablet per day for 48 weeks
Study NCT05957380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of DA-2803-R
Description: All participants are administered one tablet per day for 48 weeks
Study NCT05318417 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The Cochlear™ Nucleus® Cochlear Implant (CI) System
Description: The Cochlear™ Nucleus® CI systems are designed to provide useful hearing. The system works by converting sound in the environment into electric pulses that stimulate the auditory nerve, allowing the brain to perceive sound. The Cochlear™ Nucleus® CI system has implanted and external components.~Implanted component:~The CI is surgically implanted under the skin behind the ear. It includes a receiver/stimulator to receive and decode the electrical signals from the sound processor and an electrode to deliver these signals to the cochlear.~External components:~The external components include a sound processor, and associated accessories and cables. The system is programmed by a Cochlear proprietary programming system, Custom Sound®.
Study NCT06375551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimizing Responses with Collaborative Assessments-Automated (ORCA-A)
Description: Participants will receive automated facilitation in the ORCA platform. This will entail prompts for group discussion based on group model building scripts and decision hygiene approaches proposed by Kahneman, Sibony, and Sunstein (2021). Participants will have the option of using these prompts to discuss ORCA results in group decision discussions.~Optimizing Responses with Collaborative Assessments (ORCA) is a technical decision support tool based in multi-criteria decision analysis. Decision makers rate and compare evidence-based programs or other practices with ORCA, then prioritize practices for local implementation based on ORCA results. ORCA will be on a virtual platform to allow for web-based completion, automated analysis, and automated facilitation.
Study NCT06375551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimizing Responses with Collaborative Assessments-Live (ORCA-L)
Description: A facilitator will guide group decision discussions using group model building scripts and decision hygiene approaches proposed by Kahneman, Sibony, and Sunstein (2021). Facilitation will be either in-person or virtual, but occur live as in during real-time.~Optimizing Responses with Collaborative Assessments (ORCA) is a technical decision support tool based in multi-criteria decision analysis. Decision makers rate and compare evidence-based programs or other practices with ORCA, then prioritize practices for local implementation based on ORCA results. ORCA will be on a virtual platform to allow for web-based completion, automated analysis, and automated facilitation.
Study NCT06217510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Brace
Description: Participants will be fitted with the Test Brace and will wear the brace for 30 minutes.
Study NCT06373029 — intervention group
Intervention type: OTHER
Intervention: Ultrasound examination
Description: The investigators made ultrasound examinations to the participants to test whether the model could improve their diagnostic accuracy
Study NCT05126433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin 3.2 mg/m\^2 intravenous (IV) every 3 weeks (Q3W)
Study NCT04654065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004
Description: One time dose of IN-C004 taken orally.
Study NCT06424626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104+Axitinib
Description: Subjects receive AK104 10mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.
Study NCT06424626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112+Axitinib
Description: Subjects receive AK112 20mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.
Study NCT05884151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Group A 30 patients treated with Intradermal Tranexamic acid injection (4mg/ml) for preparation an insulin syringe was used with a volume of 1ml containing 0.04 ml of TXA and the reminder being normal saline to ensure 4mg preparation in each insulin syringe
Study NCT05884151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelets rich plasma
Description: Group B 30 patients prescribed with PRP (1ml) intra-dermally PRP was obtained manually by a two-step procedure using a centrifuge machine. First spin was performed at 1500 RPM for 10 minutes. Second spin was performed at 4000 RPM for 10 minutes. Thus, obtaining a two-part plasma. Upper two third was platelet poor plasma and was discarded. Lower one third was platelets rich plasma. Before injection applying 0.1 ml calcium chloride was added for each 1 ml of PRP to activate the platelets. PRP was injected 1 ml by using 30 G needle (insulin syringe) in each cm2 of melasma.
Study NCT05917197 — intervention group
Intervention type: OTHER
Intervention: survey based information
Description: Only survey based information collected
Study NCT06530446 — intervention group
Intervention type: OTHER
Intervention: one group. observational study
Description: observational study of this group
Study NCT05132907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HDT-301
Description: HDT-301 Investigational Vaccine (a Nanoparticle Carrier-Formulated Replicon RNA (repRNA-CoV2S))
Study NCT04857476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound scan
Description: Psoriasis epidemiology screening tool (PEST) score for completion Brief questionnaire about current psoriasis symptoms, current treatment and if any features associated with psoriatic arthritis.~One-off musculo-skeletal ultrasound Questionnaire at 2 years
Study NCT04449250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmethylphenidate
Description: Subjects will be randomized to one of two sequences. Subjects will be dosed with 25 mg dose of CTx-1301 during each sequence. Subjects will serve as their own control.
Study NCT05327296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Inhaled isoflurane administered by Sedaconda ACD-S
Study NCT05327296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous infusion of propofol
Study NCT06519487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cyberball
Description: Cyberball™ is a virtual social exclusion game that simulates social interactions and acute discrimination experiences in a controlled laboratory setting. The game involves passing a virtual ball between players represented by images. In this study, only the participant is a real player, while the other players are pre-programmed virtual avatars controlled by the experimenter using Cyberball software. The ethnicity of these virtual players can be manipulated by changing the stock photos used to represent them. Participants in the Race-Based Social Exclusion condition play Cyberball with virtual players who appear to be of a different ethnicity from the participant. In the Non-Race-Based Social Exclusion, the participant plays with virtual players who do not have any obvious ethnic differences from the participant, and social inclusion is a washout condition where the participant receives the ball from the virtual players, regardless of the ethnicity of the avatars.
Study NCT06519487 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cyberball
Description: Cyberball™ is a virtual social exclusion game that simulates social interactions and acute discrimination experiences in a controlled laboratory setting. The game involves passing a virtual ball between players represented by images. In this study, only the participant is a real player, while the other players are pre-programmed virtual avatars controlled by the experimenter using Cyberball software. The ethnicity of these virtual players can be manipulated by changing the stock photos used to represent them. Participants in the Race-Based Social Exclusion condition play Cyberball with virtual players who appear to be of a different ethnicity from the participant. In the Non-Race-Based Social Exclusion, the participant plays with virtual players who do not have any obvious ethnic differences from the participant, and social inclusion is a washout condition where the participant receives the ball from the virtual players, regardless of the ethnicity of the avatars.
Study NCT05096585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed bedtime sleep restriction
Description: bedtime 2 hr later than their normal bedtime
Study NCT05096585 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Delayed bedtime sleep restriction
Description: bedtime 2 hr later than their normal bedtime
Study NCT05096585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early wake sleep restriction
Description: wake time 2 hr earlier than their normal wake time
Study NCT05096585 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Early wake sleep restriction
Description: wake time 2 hr earlier than their normal wake time
Study NCT06526039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a novel short regimen
Description: An intensive phase consisting of isoniazid, bedaquiline, moxifloxacin and pyrazinamide for 2 months (9 weeks). A continuation phase consisting of isoniazid, bedaquiline, and levofloxacin for 4 months (17 weeks). Treatment may be extended for 3 months (13 weeks) in patients with severe disease or with delayed culture conversion, defined by culture positive at 4 months of treatment.
Study NCT05488015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education (GPR)
Description: GPR intervention lasted 8 weeks. Each week the postures had to be performed on 4 or 5 days.
Study NCT05488015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle habits
Description: No change in lifestyle habits during the 8-week trial.
Study NCT05358028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Arm Bimanual Intensive Technique including Lower Extremity (HABIT-IL)
Description: HABIT-ILE along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities.~Functional task as maintaining ADL:~i.Eating with spoon while standing ii. Combing hair while standing. iii. Counting cards while standing and putting them in box. Standing and walking I. standing with support of upper extremity II. walking with the help walkers III. walking on parallel bar playing activities: I. playing with cards while standings II. taking toys out of box and putting them in other box while standing III. grasping a fixed rod by hand and trying to maintain balance on physio stability ball
Study NCT05358028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand Arm bimanual intensive Technique (HABIT)
Description: HAIBT along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities HAIBT along with the conventional Bobth treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities~Playing activities on table:~I. building towers with Lego blocks, II. Holding book by one hand and turning pages , III. Playing games with cards, IV. Drawing random impressions on paper, V. taking toys out of one box and placing them in other box one by one~Activities of daily living :~I. eating with spoon from bowel II. combing hair while sitting, III. opening of bottle cap for drinking water Age appropriate video games while sitting will be provided according to the ease of children
Study NCT04054752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-7-hyFc (NT-I7)
Description: NT-I7 administered at escalating doses of 720, and 960g/kg to determine OBD of NT-I7
Study NCT04054752 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine sequence 1
Description: Day 1 Immunization Pre-NT-I7:Td and Polio Day 64, Immunization Post-NT-I7: Hep A#1, Hep B#1 Day 106: Hep B#2 (Optional) 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
Study NCT04054752 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine sequence 2
Description: Day 1 Immunization Pre-NT-I7: Hep A#1, Hep B#1 Day 64, Immunization Post-NT-I7:Td and Polio Day 106: no Vaccine 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
Study NCT05709015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neutral electrolyzed water
Description: Use of mouthwash containing neutral electrolyzed water twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.